ライフサイエンスコーパス: dyspepsia

1 related symptoms in patients with functional dyspepsia.

2 commodation, is also effective in functional dyspepsia.

3 n, diarrhea, vomiting, food intolerance, and dyspepsia.

4 ssant therapy may be effective in functional dyspepsia.

5 an endoscopy, but most will have functional dyspepsia.

6 other area for future research in functional dyspepsia.

7 ation for their symptoms and have functional dyspepsia.

8 ii and H. felis was low in our patients with dyspepsia.

9 ts with scores >/= 6 were considered to have dyspepsia.

10 astrointestinal reflux disease or functional dyspepsia.

11 astric pathology in patients presenting with dyspepsia.

12 sis, evaluation, and treatment of functional dyspepsia.

13 ne gastritis, gastric cancer, and functional dyspepsia.

14 e gastric accommodation, to treat functional dyspepsia.

15 gastrointestinal malignancy in patients with dyspepsia.

16 f gastric syphilis in a patient with chronic dyspepsia.

17 responsible for sensations of satiety and of dyspepsia.

18 gets for ameliorating symptoms of functional dyspepsia.

19 ia and had no other diagnosis to account for dyspepsia.

20 s commonly performed to evaluate symptoms of dyspepsia.

21 randial symptoms in patients with functional dyspepsia.

22 l sensation contribute to the development of dyspepsia.

23 ere not associated with an increased risk of dyspepsia.

24 association with the very common symptom of dyspepsia.

25 nts in irritable bowel syndrome and diabetic dyspepsia.

26 Maybe it was the Hippocratic description of dyspepsia.

27 radication therapy in patients with nonulcer dyspepsia.

28 herapy; and 5) assessed symptoms of nonulcer dyspepsia.

29 or H. pylori produced only a 5% reduction in dyspepsia.

30 s about H. pylori-seropositive patients with dyspepsia.

31 this gastritis predisposes to NSAID-related dyspepsia.

32 itial management strategy for uninvestigated dyspepsia.

33 om patients with gastritis alone or nonulcer dyspepsia.

34 l therapy in the management of patients with dyspepsia.

35 ntagonists are used to prevent recurrence of dyspepsia.

36 e management of patients with a new onset of dyspepsia.

37 has been proposed for initial management of dyspepsia.

38 r upper GI tract endoscopy in uninvestigated dyspepsia.

39 r disease occurs in 3.5-32% of patients with dyspepsia.

40 d in 35% (95% CI 31.4-39.2) of patients with dyspepsia.

41 h an increased risk of subsequent functional dyspepsia.

42 estinal disorders such as IBS and functional dyspepsia.

43 ex- and age-matched patients with functional dyspepsia.

44 models, controlling for comorbid functional dyspepsia.

45 amous epithelium of patients with functional dyspepsia.

46 e (IBS) and 23 (28.8%) had one of functional dyspepsia.

47 implicated in the pathogenesis of functional dyspepsia.

48 pecies of NHPGHs in patients presenting with dyspepsia.

49 7%) met the Rome III criteria for functional dyspepsia.

50 smoking status were associated with organic dyspepsia.

51 ny of the diagnostic criteria for functional dyspepsia.

52 ic ulcer and 56 were diagnosed as functional dyspepsia.

53 omach distention in patients with functional dyspepsia.

54 8.3% and 11.4%, respectively) and functional dyspepsia (1.9% and 3.3%, respectively).

55 BS [4.4%], 2 of 201 patients with functional dyspepsia [1%], and 1 of 311 patients with functional ab

56 ollows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal refl

57 .1%), painful conditions (15.4% vs 8.4%) and dyspepsia (10.9% vs 5.2%).

58 itable bowel syndrome = 91(4.9%), functional dyspepsia = 11 (0.6%), abdominal migraine = 37 (1.9%) an

59 , the most frequent indications for EGD were dyspepsia (19.5%), followed by hematemesis (19.06%), and

60 ticipants [19.2%] vs 2 participants [1.6%]), dyspepsia (20 participants [16.0%] vs 2 participants [1.

61 number of patients reporting nausea-vomiting-dyspepsia (20.6% vs. 8%, P=0.007), diarrhea (34.3% vs. 2

62 heral neuropathy (25 [31%] vs 14 [19%]), and dyspepsia (21 [26%] vs 9 [12%]); most were of mild-to-mo

63 bo were constipation (27 [21%] vs 13 [10%]), dyspepsia (24 [19%] vs 10 [8%]), headache (17 [14%] vs 1

64 de group), diarrhoea (36 [12%] vs 36 [12%]), dyspepsia (24 [8%] vs 18 [6%]), and vomiting (21 [7%] vs

65 most frequent grade 1-2 toxicity overall was dyspepsia (246 [11%] of 2253 participants).

66 onstipation (4%, 9%), anorexia (3%, 7%), and dyspepsia (3%, 7%).

67 ed GERD/heartburn (38.1%) and abdominal pain/dyspepsia (31.0%).

68 ious enteritis or colitis (7.4%), functional dyspepsia (6%) and ulcers (1.0%).

69 ausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 1

70 delpar 50 mg, and one on seladelpar 200 mg), dyspepsia (8%; two patients on seladelpar 50 mg and one

71 ntial for PUD (134,000 [93,000-177,000]) and dyspepsia (860,000 [196,000-1.5 million]).

72 were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory t

73 Dyspepsia, a ubiquitous condition in the United States,

74 omprise irritable bowel syndrome, functional dyspepsia, abdominal migraine and functional abdominal p

75 Outpatients with uninvestigated dyspepsia, according to Rome III criteria, answered a dy

76 Functional dyspepsia affects up to 16% of otherwise healthy individ

77 Dyspepsia affects up to 40% of the general population an

78 did not differ between groups for ulcers or dyspepsia alone, per-protocol analysis, or final H. pylo

79 he vagal nerve block group were heartburn or dyspepsia and abdominal pain attributed to therapy; all

80 ferred to gastroenterology for evaluation of dyspepsia and dysphagia.

81 haracteristic of diseases such as functional dyspepsia and gastroesophageal reflux disease (e.g. vomi

82 symptoms; trials of patients with functional dyspepsia and gastroparesis; and trials of GE test metho

83 care billing claims to identify diagnoses of dyspepsia and GERD among Medicare beneficiaries transpla

84 d studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used combination t

85 16 men) met Rome II criteria for functional dyspepsia and had no other diagnosis to account for dysp

86 A high degree of overlap with dyspepsia and IBS exists in Nigerian patients with GERD.

87 questionnaire (GERDQ) while the diagnosis of dyspepsia and IBS was based on the Rome III criteria for

88 The GERDQ and Rome III questionnaires for dyspepsia and IBS were merged into a composite questionn

89 rly in subgroups of patients with functional dyspepsia and IBS.

90 tors of GERD, and its degree of overlap with dyspepsia and irritable bowel syndrome (IBS) in Nigeria,

91 A 28-year-old woman had a 2-year history of dyspepsia and lactose intolerance.

92 racterize patients who receive endoscopy for dyspepsia and measure predictors of primary endoscopic o

93 Patients with reflux dyspepsia and nonreflux dyspepsia were identified from J

94 placed on regional gastric motor function in dyspepsia and on the role of fundic relaxation and accom

95 into the pathogenesis of chronic functional dyspepsia and provide a potential model for further stud

96 110 individuals comprising 463 controls with dyspepsia and reflux symptoms and 647 BE cases swallowed

97 f gastroesophageal reflux disease (GERD) and dyspepsia and their associations with graft survival and

98 Most AEs were mild, with nausea, dyspepsia and vomiting most commonly reported.

99 esophageal reflux disease (GERD), functional dyspepsia and, possibly, pancreatitis.

100 EGD was most commonly performed to evaluate dyspepsia and/or abdominal pain (23.7%), dysphagia (20%)

101 Overlap of GERD with dyspepsia and/or IBS was observed in over 50% of cases.

102 fied as having IBS, 201 as having functional dyspepsia, and 311 as having functional abdominal pain,

103 e chronic fatigue syndrome, skin conditions, dyspepsia, and a clinically insignificant decrease in th

104 ere acneiform rash, diarrhea, hand reaction, dyspepsia, and anemia.

105 s irritable bowel syndrome (IBS), functional dyspepsia, and functional chest pain.

106 The proportions of PUD, dyspepsia, and gastric lymphoma attributable to H pylori

107 iseases, such as peptic ulcer disease (PUD), dyspepsia, and gastric lymphomas, is often overlooked in

108 hose of eosinophilic esophagitis, functional dyspepsia, and gastroparesis, posing a challenge for pat

109 c covariates, the incidence of constipation, dyspepsia, and GERD was approximately 1.5-old higher (P

110 antly associated with chest pain, dysphagia, dyspepsia, and globus sensation.

111 -liver disease, irritable bowel syndrome and dyspepsia, and inflammatory bowel disease.

112 rpus biopsies from 60 patients with nonulcer dyspepsia, and results were correlated with the presence

113 containing information on gastric function, dyspepsia, and upper GI tract endoscopy.

114 group were constipation, nausea, dry mouth, dyspepsia, and vomiting.

115 Patients had chronic diarrhea, vomiting, dyspepsia, and weight loss for 1 month to 3 years.

116 odestly in identifying those with functional dyspepsia, and were not significantly superior to previo

117 zema/psoriasis (aOR 3.30, 95% CI 3.14-3.48), dyspepsia (aOR 2.20, 95% CI 2.15-2.25) and chronic sinus

118 However, symptoms of functional dyspepsia are often worse after a meal, so studies of po

119 wing recognition of nonulcer (or functional) dyspepsia as an entity that affects a sizable subset of

120 Omitting PUD and dyspepsia as outcomes in studies on H pylori screen-and-

121 ought to determine estimates of the risks of dyspepsia associated with NSAIDs.

122 s to compare the risk of incident functional dyspepsia between patients with and without sleep distur

123 ation contribute to postprandial symptoms in dyspepsia, but the controlling mechanisms are unclear.

124 ofenamate, or piroxicam increase the risk of dyspepsia by about 3-fold.

125 Dyspepsia can be managed by initial endoscopy and treatm

126 CI, 1.98-2.46]) and pain, osteoporosis, and dyspepsia cluster (HR, 2.00 [95% CI, 1.68-2.37]) in wome

127 2.82 ~ 3.89) increased hazard of functional dyspepsia compared with controls.

128 und pathogen-specific increased risk of IBS, dyspepsia, constipation and GERD.

129 It appears that the risk of dyspepsia, constipation, and GERD are higher among those

130 d side effects were reported in 38%; nausea, dyspepsia, constipation, and sedation were the most comm

131 Ulcer-free patients with mild dyspepsia continued NSAIDs but not antiulcer treatment.

132 %; odds ratio, 1.38 [CI, 1.06 to 1.80]), and dyspepsia (deployed, 9.1%; nondeployed, 6.0%; odds ratio

133 Eradication of H. pylori in patients with dyspepsia despite more negative trials is likely to cont

134 adication in infected patients with nonulcer dyspepsia, despite a number of negative efficacy studies

135 stemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and p

136 wn not to be associated with ulcer (nonulcer dyspepsia) do not now provide an indication for testing.

137 Although functional dyspepsia does not impart any increased risks to long-te

138 The dyspepsia-dominant group showed significantly higher fem

139 Among pediatric patients with dyspepsia evaluated by endoscopy and biopsy, those with

140 llion per year, and patients with functional dyspepsia experience a markedly reduced quality of life.

141 as to determine the prevalence of functional dyspepsia (FD) among patients with hepatitis C.

142 ; irritable bowel syndrome (IBS), functional dyspepsia (FD) and chronic fatigue (CF).

143 esophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are co

144 Symptoms suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) freque

145 quency of nausea in patients with functional dyspepsia (FD) and irritable bowel syndrome (IBS), respe

146 Current treatment for functional dyspepsia (FD) has limited and unsustainable efficacy.

147 Although functional dyspepsia (FD) is a common functional gastroduodenal dis

148 Functional dyspepsia (FD) is a functional gastrointestinal disorder

149 Functional dyspepsia (FD) is a gastrointestinal disorder characteri

150 Functional dyspepsia (FD) is associated with anxiety but it is not

151 It has been reported that functional dyspepsia (FD) is associated with homozygous genotypes o

152 In addition, functional dyspepsia (FD) is characterized by upper abdominal sympt

153 cluded in this study, including 4 Functional dyspepsia (FD) studies, 3 irritable bowel syndrome (IBS)

154 re frequently prescribed to treat functional dyspepsia (FD), a common disorder characterized by upper

155 to clarify the pathophysiology of functional dyspepsia (FD), a highly prevalent gastrointestinal synd

156 tient conditions in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and FD-I

157 rritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD), significantly impact global health, redu

158 rations in the pathophysiology of functional dyspepsia (FD), the effect and mechanism of proton pump

159 abnormalities have been noted in functional dyspepsia (FD), their pathogenesis is poorly understood.

160 d symptom relief in patients with functional dyspepsia (FD).

161 estinal and systemic symptoms, in functional dyspepsia (FD).

162 rritable bowel syndrome (IBS) and functional dyspepsia (FD).

163 epigastric pain in patients with functional dyspepsia (FD); the etiology and cellular mechanisms of

164 epigastric pain in patients with functional dyspepsia (FD); the etiology and cellular mechanisms of

165 Organic dyspepsia findings were analyzed with different variable

166 charges in the first year after the onset of dyspepsia for patients managed by initial endoscopy or e

167 a-regression identified an increased risk of dyspepsia for users of specific NSAIDs (adjusted odds ra

168 (2.39% cancer and 2.57% IBD) and lowest for dyspepsia (for cancer: 1.41% men and 1.03% women; for IB

169 The consumption of medicines for dyspepsia (from 3.7 to 2.4 pills/month) and painkillers

170 Rome III criteria as having IBS, functional dyspepsia, functional abdominal pain, or abdominal migra

171 ific estimates varied with lowest PAFs (PUD, dyspepsia, gastric lymphomas) observed in the United Sta

172 fore conclude that in patients with nonulcer dyspepsia, H. pylori carriage is associated with increas

173 CD patients with dyspepsia had significantly (p<0.05) prolonged gastric e

174 Approximately 80% of individuals with dyspepsia have no structural explanation for their sympt

175 s has been found in patients with functional dyspepsia; however, direction of causality remains uncle

176 The endoscopic diagnosis of uninvestigated dyspepsia in our setting showed a predominance of functi

177 gnosis of H. pylori infection in people with dyspepsia in resource-limited settings.

178 ly prevalent and diverse among patients with dyspepsia in Southwestern region of Saudi Arabia.

179 this infection might lower the prevalence of dyspepsia in the community and improve quality of life.

180 Five (8%) of 60 participants had dyspepsia in the placebo group.

181 more patients experienced GI issues, mainly dyspepsia, in the ibandronate arm than in the control ar

182 f abdominal pain, change in bowel habit, and dyspepsia, in those aged 60 years and over.

183 Symptoms of functional dyspepsia, including epigastric pain, early satiety, and

184 ges 8-16 years, who underwent evaluation for dyspepsia, including upper endoscopy.

185 tanding of the pathophysiology of functional dyspepsia increases, it is probable that the next decade

186 ry outcomes included quality of life (Nepean Dyspepsia Index) and symptom severity (Patient Assessmen

187 Validated Nepean dyspepsia index-short form (NDI-SF) was used to assess t

188 iarrhea, irritable bowel syndrome, non-ulcer dyspepsia, infant dyschezia, and functional constipation

189 Patients with peptic ulcer or functional dyspepsia infected by H. pylori were randomized to treat

190 While NSAIDs also cause dyspepsia, inhibition of prostaglandin synthesis may red

191 In H. pylori-seropositive patients with dyspepsia, initial anti-H. pylori therapy is the most co

192 Dyspepsia is a common complaint in upper gastrointestina

193 Dyspepsia is a complex of symptoms referable to the gast

194 Dyspepsia is a frequent syndrome in our country, where t

195 Functional dyspepsia is a heterogeneous disorder involving a number

196 Functional dyspepsia is a highly prevalent disorder that accounts f

197 is now largely accepted that noninvestigated dyspepsia is an indication for testing for and treating

198 c imaging modalities, the pathophysiology of dyspepsia is becoming better understood and recognized a

199 ere are also data to suggest that functional dyspepsia is caused by subtle manifestations of inflamma

200 rstanding of its pathophysiology, functional dyspepsia is difficult to treat and, in most patients, t

201 burden of evaluating and treating functional dyspepsia is estimated to be at least $1 billion per yea

202 inal (GI) tract endoscopy for uninvestigated dyspepsia is low, and its clinical implications are limi

203 The initial management of dyspepsia is well established, but managing those with c

204 stention, an important feature of functional dyspepsia, is assessed by stepwise balloon distention of

205 past or current peptic ulcer or troublesome dyspepsia led to impaired healing of gastric ulcers and

206 uld otherwise prevail and mask ulcer-related dyspepsia, making anticipatory management difficult.

207 Their use in dyspepsia management strategies needs further refinement

208 The pathophysiology of functional dyspepsia may involve abnormal processing of visceral st

209 Dyspepsia may result from gastroparesis and antral diste

210 expectations, psychological stress, hunger, dyspepsia, micronutrient deficiencies (Fe, Zn, and Ca),

211 esentation included epigastric pain (n = 6), dyspepsia (n = 4), and nausea and vomiting (n = 4).

212 as well tolerated, but mild GI side-effects (dyspepsia, nausea and abdominal pain) were described in

213 cific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea.

214 ere Caucasian and 89% diagnosed as non-ulcer dyspepsia (NUD).

215 n inactive duodenal ulcer (iDU) or non-ulcer dyspepsia (NUD).

216 In nonulcer dyspepsia, numerous RCTs have yielded conflicting result

217 y specimens were obtained from patients with dyspepsia on esophagogastroduodenoscopy (EGD) for rapid

218 lated problems such as functional heartburn, dyspepsia or even eosinophilic oesophagitis.

219 jaundice was associated with abdominal pain, dyspepsia or loss of appetite in 54 (53.465%) subjects.

220 mbers, or incidentally at endoscopy done for dyspepsia or reflux.

221 Dyspepsia or symptoms of gastro-oesophageal reflux were

222 -6.0), dysphagia (OR, 4.7; 95% CI, 2.9-7.4), dyspepsia (OR, 3.1; 95% CI, 1.9-5.0), and globus sensati

223 disorder such as irritable bowel, functional dyspepsia, or abdominal migraine.

224 with current or previous peptic ulceration, dyspepsia, or both who continued to use NSAIDs.

225 such as irritable bowel syndrome, functional dyspepsia, or functional constipation.

226 porting the relative risk of developing PUD, dyspepsia, or gastric lymphomas due to H pylori to calcu

227 did not affect the rate of peptic ulcers or dyspepsia over 6 months.

228 pared with usual management in patients with dyspepsia over age 50 years presenting to their primary

229 diagnosed most often with IBS (p = 0.13) or dyspepsia (p = .036).

230 thy controls and 62 patients with functional dyspepsia participated in a gastric barostat study at Le

231 and sex-matched duodenal ulcer and nonulcer dyspepsia patients (16 each).

232 hundred and sixty-four (164) uninvestigated dyspepsia patients were enrolled.

233 de, reduces dyspepsia symptoms in functional dyspepsia patients.

234 c or acute diseases, such as stomach ulcers, dyspepsia, peptic ulcers, gastroesophageal reflux, gastr

235 c fatigue syndrome, dermatologic conditions, dyspepsia, physical health-related quality of life (Shor

236 on in the United States include treatment of dyspepsia, physician education on disease associations w

237 A total of 86% met criteria for functional dyspepsia, primarily postprandial distress syndrome.

238 The Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) was used to evaluate th

239 assessed using an evaluation scale (Glasgow dyspepsia questionnaire [GDQ]), and AEs were assessed at

240 er interviewed participants with a validated dyspepsia questionnaire and the psychological general we

241 , according to Rome III criteria, answered a dyspepsia questionnaire and underwent esophagogastroduod

242 eatment group had dyspepsia; the severity of dyspepsia ranged from mild to severe, with four (21%) of

243 his cross-sectional study, 233 patients with dyspepsia, referred for endoscopy, were examined regardi

244 ro and microscopic bile reflux and impact on dyspepsia related quality of life in long-term survivors

245 (NDI-SF) was used to assess the severity of dyspepsia-related quality of life and compared with age

246 Treatment of functional dyspepsia remains a challenge.

247 relationship between H. pylori gastritis and dyspepsia remains controversial, there is no evidence fr

248 status; diagnosis (ulcer disease or nonulcer dyspepsia); resistance to clarithromycin, imidazoles, or

249 .5%) suffered from mild, moderate and severe dyspepsia, respectively.

250 x disease (GERD) (RR, 1.9; 95% CI, 1.4-2.6), dyspepsia (RR, 3.3; 95%, 1.4-7.7), and constipation (RR,

251 In the group with dyspepsia score >5 points, the ratio of patients undergo

252 In adults with functional dyspepsia seen in a tertiary referral practice, decrease

253 th the hypothesis that in such a population, dyspepsia should have been relatively less common.

254 ian patients with peptic ulcer or functional dyspepsia showed no significant difference in efficacy o

255 Further, the relationship between dyspepsia symptoms and clinical background of asthma was

256 Primary outcomes were effect of treatment on dyspepsia symptoms and cost effectiveness.

257 re exhibited by 83% of patients with asthma, dyspepsia symptoms by 44%, and reflux symptoms by 26%.

258 s that a new prokinetic, acotiamide, reduces dyspepsia symptoms in functional dyspepsia patients.

259 e, herein, we investigated the prevalence of dyspepsia symptoms in these patients.

260 Hospital and investigated the prevalence of dyspepsia symptoms using the modified Frequency Scale fo

261 proportion of patients with asthma exhibited dyspepsia symptoms, and the asthma severity in patients

262 n implicated in the generation of functional dyspepsia symptoms.

263 lar between the treatment groups, except for dyspepsia (ten [7%] in the ozanezumab group vs four [3%]

264 hat used a specifically stated definition of dyspepsia (that is, upper abdominal pain or discomfort),

265 In patients with nonulcer dyspepsia, the financial benefits of initial anti-H. pyl

266 enefit of anti-H. pylori therapy in nonucler dyspepsia, the strategy outlined in this analysis can be

267 endoscopy is required to diagnose functional dyspepsia, the utility of endoscopy in all patients with

268 st frequent adverse events were headache and dyspepsia; the majority of adverse events were mild or m

269 %) of 60 patients in the treatment group had dyspepsia; the severity of dyspepsia ranged from mild to

270 It is important to know the causes of dyspepsia to establish the therapeutic approach.

271 constipation (two [<1%] vs three [<1%]), and dyspepsia (two [<1%] vs three [<1%]).

272 t low in FODMAPs with uninvestigated chronic dyspepsia (UCD) and functional dyspeptic symptoms in a l

273 ted to relieve rheumatic symptoms, headache, dyspepsia, urinary tract inflammation, and symptoms of o

274 nt in women than men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to

275 ageal or gastric malignancy in patients with dyspepsia was associated with increasing age, male sex,

276 Organic dyspepsia was associated with infection, age and smoking

277 ed to define the presence of true functional dyspepsia was epigastric pain, early satiety or postpran

278 Functional dyspepsia was found in 66% of the patients (20% with nor

279 ms, and the asthma severity in patients with dyspepsia was higher than those in asymptomatic patients

280 Dyspepsia was not reported as an outcome in the case con

281 Dyspepsia was significantly associated with older age (p

282 most commonly abdominal pain, diarrhoea, and dyspepsia, was nearly three times higher in the diclofen

283 A medical history, including a history of dyspepsia, was taken by a physician and immunoglobulin G

284 -year cumulative incidences of GERD, RE, and dyspepsia were 20%, 5%, and 6%, respectively.

285 lthough the Rome III criteria for functional dyspepsia were defined 7 years ago, they have yet to be

286 Two hundred-fifty patients with dyspepsia were enrolled in the study.

287 act infection, back pain, muscle spasms, and dyspepsia were higher with ibrutinib, with 1.5- to 4.1-f

288 Patients with reflux dyspepsia and nonreflux dyspepsia were identified from January 2000 to June 2002

289 me, functional abdominal pain, or functional dyspepsia were randomized to 4 weeks of placebo or amitr

290 Headache, flushing, and dyspepsia were reported frequently during treatment, but

291 Headache, flushing, and dyspepsia were the most common adverse effects in the do

292 GI bleeding and dyspepsia were the most common symptoms.

293 linicians in the management of patients with dyspepsia who are seropositive for H. pylori are lacking

294 hould be offered to patients with functional dyspepsia who test positive for Helicobacter pylori.

295 criteria identified patients with functional dyspepsia with 60.7% sensitivity, 68.7% specificity, a p

296 criteria identified patients with functional dyspepsia with 71.4% sensitivity, 55.6% specificity, a p

297 ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy compared wi

298 rges than initial endoscopy if patients with dyspepsia with H. pylori receive antimicrobial therapy w

299 Dyspepsia, with and without reflux symptoms, accounted f

300 individuals with NCSRWS and 10 subjects with dyspepsia without CD and food intolerances.